Divalproex in the Treatment of Bipolar Disorder
By Paul E. Keck, Jr, MD, and Susan L. McElroy, MD
-
The Efficacy of Divalproex for Partial Epilepsies
By Michael C. Smith, MD
-
Divalproex and Epilepsy
By L. James Willmore, MD
-
Pharmacokinetics, Drug Interactions, and Tolerability of Valproate
By C. Lindsay DeVane, PharmD
-
Pharmacology of Valproate
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
-
The History of Valproate in Clinical Neuroscience
By Thomas R. Henry, MD
-
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
-
Paroxetine Treatment of Mood and Anxiety Disorders in Children and Adolescents
By Karen Dineen Wagner, MD, PhD
-
Clinical Management of Perinatal Depression: Focus on Paroxetine
By D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD
-
Paroxetine Treatment of Mood Disorders in Women: Premenstrual Dysphoric Disorder and Hot Flashes
By Kimberly A. Yonkers, MD
-
Paroxetine Treatment of Depression in Late Life
By Charles F. Reynolds III, MD
-
Paroxetine Use in Medically Ill Patients
By Steven Stout, MD, PhD, Wendy I. Somerset, MD, Andrew Miller, MD, and Dominique L. Musselman, MD, MS
-
Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective
By Murray B. Stein, MD, FRCPC
-
Obsessive-Compulsive Disorder: Implications of the Efficacy of an SSRI, Paroxetine
By Philip T. Ninan, MD
-
Treatment of Posttraumatic Stress Disorder: The Impact of Paroxetine
By Jonathan R.T. Davidson, MD
-
Paroxetine Treatment of Generalized Anxiety Disorder
By David V. Sheehan, MD, MBA, and C. Gloria Mao, PharmD
-
Treatment of Panic Disorder: Focus on Paroxetine
By Mark H. Pollack, MD and Alicia C. Doyle, BA
-
Paroxetine Treatment of Major Depressive Disorder
By Martin B. Keller, MD
-
Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR
By C. Lindsay DeVane, PharmD
-
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
By Clinton Kilts, PhD
-
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
-
Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine
By Charles B. Nemeroff, MD, PhD
-
Management of Late-Life Depression: Focus on Comorbid Conditions
By Warren D. Taylor, MD, and K. Ranga Rama Krishnan, MB, ChB
-
Gender-Specific Differences in Depression and Treatment Response
By Susan G. Kornstein, MD, Diane M. E. Sloan, PharmD, and Michael E. Thase, MD
-
New Advances in the Management of Anxiety Disorders
By Mark H. Pollack, MD
-
Neurobiology and Mechanisms of Antidepressant Treatment Response in Anxiety
By Philip T. Ninan, MD, Sarah A. Feigon, PhD, and Bettina Knight, RN
-
Strategies for Treatment-Resistant Depression
By Christos Ballas, MD, Jeffrey P. Staab, MD, MS, and Dwight L. Evans, MD
-
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
-
Remission as the Critical Outcome of Depression Treatment
By Michael E. Thase, MD, Diane M. E. Sloan, PharmD, and Susan G. Kornstein, MD
-
New Developments in Depression and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
-
Raising the Expectations of Long-Term Treatment Strategies in Anxiety Disorders
By Martin B. Keller, MD
-
Raising the Expectations of Long-Term Treatment Strategies in Anxiety Disorders
By Martin B. Keller, MD
-
Can We Distinguish Anxiety From Depression?
By David S. Baldwin, FRCPsych, Dwight L. Evans, MD, Robert M. A. Hirschfeld, MD, and Siegfried Kasper, MD
-
Unraveling the Diagnostic Clues of Depression and GAD: The Primary Care Challenge
By Johan A. den Boer, MD, Dwight L. Evans, MD, Sing Lee, MD, PhD, and Rafael Salin-Pascual, MD
-
Algorithms in Clinical Psychiatry: A Stepped Approach Toward the Path to Recovery
By Madhukar Trivedi, MD
-
Depression Treatment: A Lifelong Commitment?
By Martin B. Keller, MD, and Ernst R. Berndt, PhD
-
Mechanism of Action of Antidepressants
By Francesc Artigas, PhD, David J. Nutt, MD, PhD, and Richard Shelton, MD
-
Depression in the Elderly
By William M. McDonald, MD, Carl Salzman, MD, and Alan F. Schatzberg, MD
-
Coping With Somatic Comorbidities: Striving for Complete Recovery
By Christer Allgulander, MD, and Siegfried Kasper, MD
-
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
By Michael E. Thase, MD, and Madhukar Trivedi, MD
-
Long-Term Treatment Strategies in Anxiety Disorders
By Christer Allgulander, MD, Robert M. A. Hirschfeld, MD, and David J. Nutt, MD, PhD
-
Generalized Anxiety Disorder: Raising the Expectations of Treatment
By Christer Allgulander, MD, and David V. Sheehan, MD, MBA
-
New Developments in the Neurobiological Basis of Anxiety Disorders
By Jack M. Gorman, MD, Robert M. A. Hirschfeld, MD, and Philip T. Ninan, MD
-
Long-Term Treatment Strategies in Affective Disorders
By Martin B. Keller, MD
-
New Goals in the Treatment of Depression: Moving Toward Recovery By Michael E. Thase, MD, and Philip T. Ninan, MD By Michael E. Thase, MD, and Philip T. Ninan, MD -
Recent Advances in the Neurobiology of Depression
By Charles B. Nemeroff, MD, PhD
-
Remission: Today’s Target in the Treatment of Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
-
Comparing the Methods Used to Compare Antidepressants
By Michael E. Thase, MD
-
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
-
Intermittent Fluoxetine Dosing in the Treatment of Women With Premenstrual Dysphoria
By Meir Steiner, MD, PhD, FRCPC, Marilyn Korzekwa, MD, FRCPC, John Lamont, MD, MSc, FRCSC, and Annette Wilkins, BA
-
Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR
By Lindsay DeVane, PharmD
-
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
-
A Discussion on the Methodologies Used to Evaluate Antidepressants
MODERATOR: Jan A. Fawcett, MD
DISCUSSANTS: Norman Sussman, MD Jeffrey H. Newcorn, MD
-
Risperidone: Review of Its Therapeutic Utility in Depression
By Joyce E. Myers, MD, and Michael E. Thase, MD
-
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
By Mikael Landén, MD, PhD, and Michael E. Thase, MD
